{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:15:48Z","timestamp":1790363748152,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cpet.2025.08.004","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:55:44Z","timestamp":1761317744000},"page":"101-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Verification, Validation, and Uncertainty Quantification (VVUQ) of Physiologically Based Pharmacokinetic Models for Theranostic Digital Twins"],"prefix":"10.1016","volume":"21","author":[{"given":"Nouran R.R.","family":"Zaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deni","family":"Hardiansyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Yusufaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Rahmim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cpet.2025.08.004_bib1","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: a roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"The lancet oncology"},{"issue":"5","key":"10.1016\/j.cpet.2025.08.004_bib2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.123.265670","article-title":"What is theranostics?","volume":"64","author":"Weber","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2025.08.004_bib3","article-title":"Theranostics in perspective: white paper","volume":"125","author":"Stokkel","year":"2025","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2025.08.004_bib4","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: Lutetium Lu 177 vipivotide Tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.cpet.2025.08.004_bib5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cpet.2025.08.004_bib6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2967\/jnumed.124.268186","article-title":"Computational nuclear oncology toward precision radiopharmaceutical therapies: ethical, regulatory, and socioeconomic dimensions of Theranostic digital twins","volume":"66","author":"Strigari","year":"2025","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2025.08.004_bib7","first-page":"3516","article-title":"Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk","volume":"45","author":"Jim\u00e9nez-Franco","year":"2018","journal-title":"Medical physics (Lancaster)"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2967\/jnumed.118.210377","article-title":"Modeling and predicting tumor response in radioligand therapy","volume":"60","author":"Kletting","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2967\/jnumed.124.268457","article-title":"Mathematic Modeling of Tumor Growth during [ 177 Lu]Lu-PSMA Therapy: insights into Treatment Optimization","volume":"66","author":"Zaid","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2025.08.004_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2023.103192","article-title":"Time-Activity data fitting in molecular radiotherapy: methodology and pitfalls","volume":"117","author":"Ivashchenko","year":"2024","journal-title":"Phys Med"},{"key":"10.1016\/j.cpet.2025.08.004_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106838","article-title":"Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration","volume":"200","author":"Sun","year":"2024","journal-title":"Eur J Pharmaceut Sci"},{"issue":"8","key":"10.1016\/j.cpet.2025.08.004_bib12","first-page":"528","article-title":"Mathematical modeling of in vivo alpha particle generators and chelator stability","volume":"38","author":"Zaid","year":"2023","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib13","doi-asserted-by":"crossref","first-page":"20041","DOI":"10.1038\/s41598-019-56603-8","article-title":"The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: a simulation study using a PBPK model","volume":"9","author":"Begum","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpet.2025.08.004_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1062592","article-title":"Theranostic digital twins for personalized radiopharmaceutical therapies: reimagining theranostics via computational nuclear oncology","volume":"12","author":"Rahmim","year":"2022","journal-title":"Frontiers in oncology"},{"issue":"9","key":"10.1016\/j.cpet.2025.08.004_bib15","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.7150\/thno.93973","article-title":"Theranostic digital twins: concept, framework and roadmap towards personalized radiopharmaceutical therapies","volume":"14","author":"Abdollahi","year":"2024","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40658-020-00311-0","article-title":"Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry","volume":"7","author":"Rinscheid","year":"2020","journal-title":"EJNMMI Phys"},{"issue":"18","key":"10.1016\/j.cpet.2025.08.004_bib17","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.7150\/thno.77279","article-title":"Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review","volume":"12","author":"Siebinga","year":"2022","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.cpet.2025.08.004_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1023\/A:1011907920641","article-title":"Modeling of pharmacokinetic\/pharmacodynamic (PK\/PD) relationships : concepts and perspectives","volume":"16","author":"DERENDORF","year":"1999","journal-title":"Pharm Res"},{"issue":"18","key":"10.1016\/j.cpet.2025.08.004_bib19","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3390\/cancers16183120","article-title":"Model-Informed radiopharmaceutical therapy optimization: a Study on the impact of PBPK model parameters on physical, biological, and statistical measures in 177Lu-PSMA therapy","volume":"16","author":"Abdollahi","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.1013","article-title":"Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective","volume":"104","author":"Shebley","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cpet.2025.08.004_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.708299","article-title":"Reviewing data integrated for PBPK model development to predict metabolic drug-drug interactions: shifting perspectives and emerging trends","volume":"12","author":"Abouir","year":"2021","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.cpet.2025.08.004_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/psp4.12134","article-title":"Applied concepts in PBPK modeling: how to build a PBPK\/PD model","volume":"5","author":"Kuepfer","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cpet.2025.08.004_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2024.103299","article-title":"A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE: comparison of model implementations in SAAM II and MATLAB\/SimBiology","volume":"119","author":"Vasi\u0107","year":"2024","journal-title":"Phys Med"},{"issue":"3","key":"10.1016\/j.cpet.2025.08.004_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2967\/jnumed.109.067546","article-title":"Radioimmunotherapy with Anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model","volume":"51","author":"Kletting","year":"2010","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2025.08.004_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127934","article-title":"Physiologically based pharmacokinetic modeling is essential in 90Y-Labeled Anti-CD66 radioimmunotherapy","volume":"10","author":"Kletting","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.cpet.2025.08.004_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162303","article-title":"Investigating the effect of ligand amount and injected therapeutic activity: a simulation Study for 177Lu-Labeled PSMA-Targeting peptides","volume":"11","author":"Kletting","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41181-024-00251-5","article-title":"Correction: physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding","volume":"9","author":"Fele-Paranj","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"12","key":"10.1016\/j.cpet.2025.08.004_bib28","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/pharmaceutics13122132","article-title":"A physiologically based pharmacokinetic model for in vivo alpha particle generators targeting neuroendocrine tumors in mice","volume":"13","author":"Zaid","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13550-021-00821-7","article-title":"A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors","volume":"11","author":"Siebinga","year":"2021","journal-title":"EJNMMI Res"},{"issue":"8","key":"10.1016\/j.cpet.2025.08.004_bib30","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/psp4.12914","article-title":"Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu-PSMA-617 in prostate cancer patients","volume":"12","author":"Siebinga","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.zemedi.2022.06.004","article-title":"Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model","volume":"33","author":"Hardiansyah","year":"2023","journal-title":"Z Med Phys"},{"key":"10.1016\/j.cpet.2025.08.004_bib32","doi-asserted-by":"crossref","unstructured":"Sargent RG, \"Verification and validation of simulation models,\" Proceedings of the 2010 Winter Simulation Conference; Baltimore (MD), 2010, 166-183.","DOI":"10.1109\/WSC.2010.5679166"},{"key":"10.1016\/j.cpet.2025.08.004_bib33","series-title":"Simulation model verification and validation: increasing the users\u2019 confidence","author":"Robinson","year":"1997"},{"issue":"11","key":"10.1016\/j.cpet.2025.08.004_bib34","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/ncb1497","article-title":"Physicochemical modelling of cell signalling pathways","volume":"8","author":"Aldridge","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"11","key":"10.1016\/j.cpet.2025.08.004_bib35","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40262-019-00790-0","article-title":"Requirements to establishing confidence in physiologically based pharmacokinetic (PBPK) models and overcoming some of the challenges to meeting them","volume":"58","author":"Peters","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.cpet.2025.08.004_bib36","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s11095-022-03250-w","article-title":"Quality assurance of PBPK modeling platforms and guidance on building, evaluating, verifying and applying PBPK models prudently under the umbrella of qualification: why, when, what, how and by whom?","volume":"39","author":"Frechen","year":"2022","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.cpet.2025.08.004_bib37","series-title":"Pharmacokinetic-Pharmacodynamic modeling and simulation","author":"Bonate","year":"2011"},{"issue":"10","key":"10.1016\/j.cpet.2025.08.004_bib38","first-page":"102504","article-title":"Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient","volume":"40","author":"Kletting","year":"2013","journal-title":"Medical physics (Lancaster)"},{"key":"10.1016\/j.cpet.2025.08.004_bib39","article-title":"External evaluation of published population pharmacokinetic models of posaconazole","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.cpet.2025.08.004_bib40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF03261932","article-title":"Fundamentals of population pharmacokinetic modelling: validation methods","volume":"51","author":"Sherwin","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.cpet.2025.08.004_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"10.1016\/j.cpet.2025.08.004_bib42","first-page":"4285","article-title":"Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test","volume":"34","author":"Glatting","year":"2007","journal-title":"Medical physics (Lancaster)"},{"key":"10.1016\/j.cpet.2025.08.004_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fphar.2011.00031","article-title":"A workflow for global sensitivity analysis of PBPK models","volume":"2","author":"McNally","year":"2011","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpet.2025.08.004_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbs.2020.108306","article-title":"Sensitivity analysis methods in the biomedical sciences","volume":"323","author":"Qian","year":"2020","journal-title":"Math Biosci"},{"issue":"5","key":"10.1016\/j.cpet.2025.08.004_bib45","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.febslet.2005.01.009","article-title":"In silico identification of the key components and steps in IFN-\u03b3 induced JAK-STAT signaling pathway","volume":"579","author":"Zi","year":"2005","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.cpet.2025.08.004_bib46","first-page":"556","article-title":"Important pharmacokinetic parameters for individualization of 177Lu-PSMA therapy: a global sensitivity analysis for a physiologically-based pharmacokinetic model","volume":"48","author":"Hardiansyah","year":"2021","journal-title":"Medical physics (Lancaster)"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s40658-025-00726-7","article-title":"Accuracy and precision analyses of single-time-point dosimetry utilising physiologically-based pharmacokinetic modelling and non-linear mixed-effects modelling","volume":"12","author":"Budiansah","year":"2025","journal-title":"EJNMMI Phys"},{"issue":"5","key":"10.1016\/j.cpet.2025.08.004_bib47","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2967\/jnumed.107.048132","article-title":"Uncertainties in internal dose calculations for radiopharmaceuticals","volume":"49","author":"Stabin","year":"2008","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2025.08.004_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/toxsci\/kfm100","article-title":"Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation","volume":"99","author":"Barton","year":"2007","journal-title":"Toxicol Sci"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib49","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2967\/jnumed.115.160713","article-title":"Uncertainty quantification in internal dose calculations for seven selected radiopharmaceuticals","volume":"57","author":"Spielmann","year":"2016","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1016\/j.cpet.2025.08.004_bib50","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00259-018-4136-7","article-title":"EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations","volume":"45","author":"Gear","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.cpet.2025.08.004_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.landig.2025.02.004","article-title":"Medical digital twins: enabling precision medicine and medical artificial intelligence","volume":"7","author":"Sad\u00e9e","year":"2025","journal-title":"Lancet Digital health"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41746-024-01073-0","article-title":"Digital twins for health: a scoping review","volume":"7","author":"Katsoulakis","year":"2024","journal-title":"npj Digit Med"},{"issue":"1","key":"10.1016\/j.cpet.2025.08.004_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-025-01447-y","article-title":"Survey and perspective on verification, validation, and uncertainty quantification of digital twins for precision medicine","volume":"8","author":"Sel","year":"2025","journal-title":"npj Digit Med"},{"key":"10.1016\/j.cpet.2025.08.004_bib55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fgene.2018.00031","article-title":"Digital twins in health care: ethical implications of an emerging engineering paradigm","volume":"9","author":"Bruynseels","year":"2018","journal-title":"Front Genet"},{"issue":"4","key":"10.1016\/j.cpet.2025.08.004_bib56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0928-0987(99)00024-X","article-title":"Validation of a population pharmacokinetic\/pharmacodynamic model for 5\u03b1-reductase inhibitors","volume":"8","author":"Olsson Gisleskog","year":"1999","journal-title":"Eur J Pharmaceut Sci"},{"issue":"2","key":"10.1016\/j.cpet.2025.08.004_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/psp4.12166","article-title":"Report from the EMA workshop on qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation","volume":"6","author":"Zhao","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cpet.2025.08.004_bib58","unstructured":"US Food and Drug Administration. Physiologically Based Pharmacokinetic Analyses\u2014Format and Content: Guidance for Industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; Silver Spring (MD): 2023. Available at: https:\/\/www.fda.gov\/media\/101469\/download."}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859825000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859825000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:45:43Z","timestamp":1763768743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859825000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1556859825000847"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2025.08.004","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Verification, Validation, and Uncertainty Quantification (VVUQ) of Physiologically Based Pharmacokinetic Models for Theranostic Digital Twins","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2025.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}